AlphaFold predicted structure
NEUROD2 · Q15784

Mean pLDDT
60.1/ 100
Low
382 residues
Confidence breakdown
- Very high(≥ 90)22%
- Confident(70–90)6%
- Low(50–70)25%
- Very low(< 50)48%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
neuronal differentiation 2
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Early onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedgenetic developmental and epileptic encephalopathy
early-infantile DEE
neurodegenerative disease
hereditary disease
type 2 diabetes mellitus
smoking initiation
diabetes mellitus
metabolic dysfunction-associated steatotic liver disease
undetermined early-onset epileptic encephalopathy
Dysequilibrium syndrome
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Neurogenic differentiation factor 2
Transcriptional regulator implicated in neuronal determination. Mediates calcium-dependent transcription activation by binding to E box-containing promoter. Critical factor essential for the repression of the genetic program for neuronal differentiation; prevents the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Induces transcription of ZEB1, which in turn represses neuronal differentiation by down-regulating REST expression. Plays a role in the establishment and maturation of thalamocortical connections; involved in the segregation of thalamic afferents into distinct barrel domains within layer VI of the somatosensory cortex. Involved in the development of the cerebellar and hippocampal granular neurons, neurons in the basolateral nucleus of amygdala and the hypothalamic-pituitary axis. Associates with chromatin to the DPYSL3 E box-containing promoter (By similarity)
NEUROD2 · Q15784

Mean pLDDT
60.1/ 100
Low
382 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0